Table 2. Baseline metabolic profiles and medications of subjects with/without contrast-induced nephropathy (CIN).
| No CIN | With CIN | ||
| n = 59 | n = 18 | P value | |
| Cholesterol (mg/dL) | 172±46 | 160±23 | 0.173 |
| LDL-C (mg/dL) | 109±39 | 96±26 | 0.252 |
| HDL-C (mg/dL) | 45±21 | 37±11 | 0.171 |
| Triglyceride (mg/dL) | 117±70 | 111±70 | 0.754 |
| Creatinine (mg/dL) | 1.1±0.4 | 1.4±1.2 | 0.365 |
| eGFR, ml/min/1.73 m2 | 68±27 | 65±32 | 0.692 |
| ALT (U/L) | 33±35 | 30±33 | 0.731 |
| Fasting glucose (mg/dL) | 143±67 | 152±62 | 0.632 |
| Body mass index (kg/m2) | 26.0±4.2 | 25.0±4.1 | 0.360 |
| Medication, n (%) | |||
| Aspirin | 52 (88.1%) | 14 (77.8%) | 0.272 |
| Clopidogrel | 42 (71.2%) | 10 (55.6%) | 0.256 |
| Cilostazol | 21 (35.6%) | 7 (38.9%) | 0.787 |
| ACEI | 9 (15.3%) | 4 (22.2%) | 0.488 |
| ARB | 23 (39.0%) | 5 (27.8%) | 0.576 |
| CCB | 25 (42.3%) | 8 (44.4%) | 0.876 |
| Beta blocker | 19 (32.2%) | 8 (44.4%) | 0.402 |
| Diuretics | 15 (25.4%) | 4 (22.2%) | 0.783 |
| Insulin | 5 (8.5%) | 3 (16.7%) | 0.381 |
| Statins | 31(52.5%) | 6 (33.3%) | 0.185 |
| Nitrates | 31 (52.5%) | 7 (38.9%) | 0.421 |
Values are presented as mean ± standard deviation (SD) or number (%).
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; ALT: alanine aminotransferase; γGT: gamma-glutamyl-transferase; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker.